SR9009 has no established human dosage because it has never completed a human clinical trial. Every dose figure in the scientific literature comes from mice, rats, or cell cultures, and the numbers most commonly reported range from 10 mg/kg to 100 mg/kg of body weight given by injection. That gap between animal research and human application is wider for SR9009 than for many experimental compounds, partly because of a serious bioavailability problem that makes oral dosing in animals unreliable and partly because the compound’s effects touch so many systems at once that safety profiling is genuinely complicated.
How SR9009 Works
SR9009 activates a pair of proteins called REV-ERBα and REV-ERBβ, which act as internal timekeepers in cells. These proteins help regulate the body’s circadian clock, the roughly 24-hour cycle that influences when you sleep, when you burn fat, how your immune system behaves, and how your liver processes cholesterol. By switching REV-ERBs into a more active state, SR9009 essentially tells cells to behave as though a particular phase of the circadian cycle is in full swing, even when it is not.
That single mechanism fans out into a surprisingly long list of downstream effects in animal studies: changes in fat metabolism, cholesterol levels, inflammation, endurance, sleep architecture, and even tumor growth. The breadth of those effects is what makes SR9009 interesting to researchers across very different fields, but it is also what makes dosing particularly tricky. A dose that produces a desirable metabolic shift could simultaneously disrupt sleep or suppress immune signaling in ways that have not been fully mapped.
Doses Used in Animal Studies
The most frequently cited dose in mouse research is 100 mg/kg, delivered by intraperitoneal injection, which means directly into the abdominal cavity. In one widely referenced Alzheimer’s disease study, mice received 100 mg/kg once daily for 14 days before behavioral testing began.1PLOS ONE. Pharmacological activation of the nuclear receptor REV-ERB reverses cognitive deficits and reduces amyloid-β burden in a mouse model of Alzheimer’s disease That same 100 mg/kg figure appears in studies on atherosclerosis, cholesterol, and liver disease, making it something of a default in the field.
A smaller number of studies have explored lower doses. One chronic-dosing experiment used 10 mg/kg daily for eight weeks in mice exposed to constant light, a protocol designed to disrupt circadian rhythms and promote weight gain. At that lower dose, the treated mice gained less weight and showed reduced insulin resistance and less white fat accumulation, though there was no significant change in overall energy balance.2PubMed Central. Chronic low-dose REV-ERBs agonist SR9009 mitigates constant light-induced weight gain and insulin resistance via adipogenesis modulation The fact that measurable metabolic effects appeared at one-tenth the standard dose hints at a dose-response curve, but too few studies have systematically varied the dose to draw it with any confidence.
Converting mouse doses to human-equivalent doses is not straightforward multiplication. Body surface area scaling, metabolic rate differences, and species-specific drug handling all factor in, and those calculations assume the drug reaches the bloodstream in the same way in both species. For SR9009, that assumption runs into a major obstacle.
The Bioavailability Problem
SR9009’s oral bioavailability in rodents is very low. When swallowed rather than injected, most of the compound appears to be broken down or excreted before it can reach circulation in meaningful amounts. This is why nearly every published study uses intraperitoneal injection rather than oral dosing. The handful of studies that have explored oral routes typically use much higher doses or specialized delivery methods to compensate.
This matters for anyone trying to translate animal findings to human use because injection is not a practical route for most people, and swallowing a capsule of SR9009 likely delivers far less active compound to the bloodstream than an equivalent milligram dose given by injection. Without published pharmacokinetic data in humans showing how much actually reaches circulation after oral ingestion, any dosing number for oral use is essentially a guess. Some online communities have settled on ranges through anecdotal self-experimentation, but those numbers lack the controlled measurement that would make them meaningful.
Metabolic Effects in Animals
The metabolic findings from animal studies are where SR9009 built its reputation, and they are genuinely striking for a single compound. In diet-induced obese mice, REV-ERB agonist treatment reduced obesity by lowering fat mass and produced marked improvements in both abnormal blood lipid levels and high blood sugar.3PubMed Central. Regulation of circadian behaviour and metabolism by synthetic REV-ERB agonists A separate study looking specifically at cholesterol found that SR9009 cut total cholesterol by about 36 to 43 percent, LDL cholesterol by roughly 41 percent, and triglycerides by 39 to 40 percent in two different mouse models.4PubMed Central. Rev-erb Regulation of Cholesterologenesis
Those cholesterol reductions are large by the standards of experimental metabolic drugs, and the mechanism appears to involve direct suppression of genes in the cholesterol-manufacturing pathway rather than simply increasing cholesterol clearance. The effect on triglycerides tracked closely with the cholesterol findings, suggesting a broad dampening of lipid production in the liver.
Endurance and Mitochondrial Effects
SR9009’s “exercise in a pill” reputation comes from early mouse studies showing that treatment for 30 days significantly prolonged running times. A single injection was enough to increase the expression of genes tied to fat burning and ramp up mitochondrial activity, while longer treatment boosted overall energy consumption without changing the ratio of fat to carbohydrate being used as fuel. In heart muscle cells treated in the lab, SR9009 increased the number of mitochondria per cell.5Trends in Pharmacological Sciences. Exercise pills: promising candidates for the second best thing to exercise
What sets this apart from other experimental endurance enhancers is the pathway involved. Rather than switching muscle fibers from one type to another, SR9009 appears to trigger mitochondrial growth through a chain of cellular energy sensors, ultimately landing on the same master regulator that exercise itself activates. The end result in mice resembles some of the cellular adaptations you would see after weeks of aerobic training, though whether the functional benefits translate beyond a laboratory treadmill test remains an open question. The compound’s potential to enhance athletic performance is the reason it landed on the radar of anti-doping authorities.
Sleep and Circadian Architecture
Because REV-ERBs sit at the core of the circadian clock, activating them with SR9009 predictably changes sleep patterns. In mice, injection of SR9009 during the light period (their normal sleep phase) induced wakefulness and suppressed both slow-wave sleep and REM sleep.6PubMed Central. Pharmacological targeting of the mammalian clock regulates sleep architecture and emotional behaviour The effect was time-dependent: mice showed increased alertness when dosed at certain points in their light cycle but not others, and the sleep disruption did not bleed into the following dark period. Their normal sleep-wake pattern re-synchronized roughly 12 hours after dosing.7PubMed Central. Pharmacological Targeting the REV-ERBs in Sleep/Wake Regulation
Repeated dosing extended the time it took for mice to recover their REM sleep, suggesting a cumulative effect on sleep regulation rather than a simple one-and-done alertness boost. The researchers framed this as evidence that REV-ERB targeting could help maintain wakefulness when needed, but the flip side is obvious: a compound that suppresses REM sleep could cause problems if timing and dose are not carefully controlled. REM sleep is not optional for long-term brain health, and chronic suppression would be a significant concern in any eventual human application.
SR9009 and the closely related compound SR9011 produced very similar sleep-wake profiles, with the only notable distinction being a brief delay in one specific sleep parameter after SR9009 administration.8PubMed Central. Pharmacological targeting of the mammalian clock regulates sleep architecture and emotional behaviour That near-identical activity pattern across two structurally distinct REV-ERB agonists strengthens the case that the sleep effects are genuinely driven by REV-ERB activation rather than off-target drug activity.
Anti-Inflammatory Activity
SR9009 consistently dampens inflammatory signaling in animal and cell studies, through a mechanism tied directly to its clock-regulating activity. In macrophages, the immune cells that drive much of the body’s inflammatory response, SR9009 suppressed the production of key inflammatory molecules. One study found it specifically blocked the inflammasome pathway responsible for producing interleukin-1β and interleukin-18, two signaling molecules heavily involved in tissue-damaging inflammation, and this suppression depended on the clock protein BMAL1.9PubMed. REV-ERBα agonist SR9009 suppresses IL-1β production in macrophages through BMAL1-dependent inhibition of inflammasome
In the gut, SR9009 shifted macrophages away from a pro-inflammatory state and toward an anti-inflammatory state, a shift that alleviated intestinal inflammation in obese mice with ulcerative colitis.10PubMed Central. SR9009 regulates macrophage polarization via the NR1D1/NF-κB axis to ameliorate obesity-associated ulcerative colitis In the brain, SR9009 suppressed hippocampal neuroinflammation triggered by a bacterial toxin challenge, while mice lacking the REV-ERBα protein entirely showed exaggerated brain inflammation in response to the same challenge.11PubMed Central. Circadian clock protein Rev-erbα regulates neuroinflammation
The anti-inflammatory profile is broad enough that it is hard to say whether it would be a net benefit or a risk for a given person. Acute inflammation is how the body fights infection and heals injuries; suppressing it at the wrong time or to the wrong degree could be harmful. The animal studies use clean laboratory models of disease, not the messy reality of a human immune system dealing with multiple simultaneous challenges.
Liver Protection and Fibrosis
Liver disease is one area where SR9009’s combination of metabolic and anti-inflammatory effects converges in a particularly promising way. In a mouse model of non-alcoholic steatohepatitis (fatty liver disease that has progressed to inflammation and scarring), SR9009 treatment reduced both liver inflammation and fibrosis. The amount of collagen, the structural protein that builds up during scarring, was significantly lower in treated animals, leading the researchers to conclude that the drug halted disease progression in that model.12PubMed Central. REV-ERB agonism improves liver pathology in a mouse model of NASH
A separate line of research using human liver cells in culture found that SR9009 prevented fat accumulation, corrected disrupted clock-gene expression, and blocked the activation of a fibrosis-driving signaling pathway called TGF-β.13PubMed Central. Targeting the liver clock improves fibrosis by restoring TGF-β signaling Taken together, the mouse and cell data suggest that REV-ERB activation could address fatty liver disease from multiple angles simultaneously: reducing the fat load, calming the inflammation that makes fat deposits dangerous, and slowing the scarring that eventually destroys liver function. No liver-targeted drug currently on the market does all three.
Cardiovascular Research
Atherosclerosis, the buildup of plaque in arteries, sits at the intersection of cholesterol metabolism and chronic inflammation, both of which SR9009 modifies in animals. In LDL-receptor-deficient mice fed a high-fat diet, seven weeks of SR9009 at 100 mg/kg reduced atherosclerotic plaque size by about 23 percent compared to untreated controls.14PubMed Central. Suppression of atherosclerosis by synthetic REV-ERB agonist Given the cholesterol-lowering data from other studies, part of this effect likely comes from simply having less cholesterol available to deposit in artery walls, but the anti-inflammatory component probably contributes as well, since inflammation is what converts a fatty streak into a dangerous plaque.
Cancer Research
The most provocative early data involves small-cell lung cancer, an aggressive cancer type with limited treatment options. Researchers found that SR9009 was lethal to both chemotherapy-sensitive and chemotherapy-resistant small-cell lung cancer cells. The mechanism traced back to an autophagy gene called Atg5, which REV-ERBα directly suppresses. Autophagy is the cellular recycling process that cancer cells often hijack to survive under stress; by shutting it down, SR9009 removed a key survival tool from the cancer cells.15PubMed Central. SR9009 induces a REV-ERB dependent anti-small-cell lung cancer effect through inhibition of autophagy
The fact that chemoresistant cells were also vulnerable is noteworthy because resistance to standard chemotherapy is one of the main reasons small-cell lung cancer is so deadly. But these findings come from cells in dishes and mice with implanted tumors. The distance from a cell-culture result to a working cancer treatment in humans is enormous, and many compounds that kill cancer cells in the lab fail completely once they enter clinical testing.
Anti-Doping Status and Athletic Misuse
SR9009 is classified as a prohibited substance by the World Anti-Doping Agency under the category of metabolic modulators. Its potential to enhance endurance through mitochondrial biogenesis and fat oxidation puts it alongside other experimental compounds flagged as threats to fair competition.16PubMed. Emerging drugs affecting skeletal muscle function and mitochondrial biogenesis – Potential implications for sports drug testing programs Anti-doping laboratories have developed methods to detect SR9009 and its breakdown products in biological samples. In one case involving equine racing, researchers identified six metabolites of SR9009 and confirmed a positive finding for one of them in both plasma and urine samples from a horse.17PubMed. In vitro metabolism of the REV-ERB agonist SR-9009 and subsequent detection of metabolites in associated routine equine plasma and urine doping control samples
The anti-doping classification is worth understanding even if you are not an athlete. It reflects an institutional judgment that SR9009 has the pharmacological profile to enhance physical performance, which in turn means it has the pharmacological profile to cause meaningful physiological changes. Substances do not get banned for having no effect. At the same time, prohibition does not imply that a compound is safe or effective at any particular dose in humans. It simply means that credible evidence of performance-altering potential exists.
Why There Are No Human Dosing Numbers
The absence of human dosing data is not just a gap that will be filled next year. Several structural obstacles stand in the way. First, the oral bioavailability problem means that any human trial would either need to use injection, which limits the target population and raises safety-monitoring costs, or would need to develop a new formulation that gets enough compound into the bloodstream by mouth. Second, because SR9009 touches the circadian clock, its effects are time-of-day dependent. An effective and safe dose given in the morning could produce very different effects given at night, which multiplies the number of dosing variables a trial would need to control. Third, the breadth of affected systems, from sleep to immunity to cholesterol to glucose, means that any human safety trial would need to monitor an unusually wide panel of outcomes to catch unexpected problems.
The compound is also not patented in a way that gives a single pharmaceutical company a strong financial incentive to fund the expensive clinical trials needed. Many experimental compounds with promising animal data stall at exactly this stage, not because the science is bad but because the economics of drug development do not reward the investment. Some researchers have pivoted toward developing next-generation REV-ERB agonists with better oral bioavailability and more selective activity, which could eventually make human trials more feasible, but that work is still in early stages.
Risks of Self-Experimentation
Despite the lack of clinical data, SR9009 is available through gray-market research-chemical vendors, and online communities share dosing protocols based on personal experience. The risks of following those protocols are real and not limited to the obvious concern that you do not know what dose is safe. You also do not know what dose is in the product. Research chemicals sold outside the pharmaceutical supply chain have no manufacturing standards, and independent analyses of gray-market compounds routinely find products that contain the wrong dose, the wrong compound, or contaminants.
Even setting aside product quality, self-dosing SR9009 means intervening in your circadian clock without the ability to monitor the downstream effects. The animal literature shows that SR9009 suppresses REM sleep, alters immune cell behavior, changes cholesterol synthesis, and modifies glucose handling. Some of those effects might be desirable in the short term, but they could compound unpredictably over weeks or months. The low-dose chronic study mentioned earlier used 10 mg/kg in mice for eight weeks and saw metabolic changes without overt toxicity, but “no obvious harm in mice at one specific dose over two months” is a low bar for assuming safety in a human taking an unregulated product of uncertain purity for an indefinite period.
The animal research on SR9009 is genuinely interesting and spans enough independent findings across enough different disease models to suggest that REV-ERB agonism is a real therapeutic avenue worth pursuing. But the compound itself remains a laboratory tool, not a finished drug, and the jump from 100 mg/kg injected into a mouse to a capsule swallowed by a person is not a calculation anyone has reliably made.